Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.39 million versus the consensus estimate of $1.22 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Designer Brands Inc. (DBI) Tops Q2 EPS by 8c, Misses on Revenue; Offers FY27 EPS Guidance
• Academy Sports & Outdoors Inc. (ASO) PT Raised to $47 at BMO Capital